[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urothelial-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urothelial-neoplasm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100582479","the-evaluation-of-molecular-markers-from-predittivi-dna-of-clinical-outcomes-in-patients-with-urothelial-tumor-100582479",false,"NCT06863844","The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor","Study for the Evaluation of Molecular Markers Extracted From PRedittivI DNA of Clinical Outcomes and Response to Systemic Therapy in Patients With UROthelial Tumor.","PROCURO","Inclusion Criteria For the retrospective part:\n\n\\- Patients diagnosed with locally advanced operated or metastatic urothelial cancer in follow-up or treatment\n\nExclusion Criteria For the retrospective part:\n\n\\- Deceased patients who have not already performed the NGS analysis from clinical practice.\n\nFor the prospective part:\n\nPatients\n\n* aged \\> 18 years\n* suffering from locally advanced or metastatic urothelial neoplasia\n* with the availability of tumor tissue obtained during surgery on a primary tumor or metastasis or during a diagnostic biopsy.\n\nPatients included in the study will also have to consciously express their willingness to participate in the study after signing the written informed consent.","ALL","18 Years",{"count":20,"type":21},210,"ESTIMATED","2 Years","OBSERVATIONAL","The genetic characterization of urothelial tumor disease has brought to light important information about the biology of the disease. The evaluation of molecular DNA markers on tumor tissue could be an approach able to provide important information on the possible aggressiveness of the disease and the sensitivity\u002Fresistance profile to drugs commonly adopted in the advanced stage. The main objective of this study is to identify specific molecular profiles from DNA capable of predicting the clinical course of the disease and the possible sensitivity\u002Fresistance of the disease to systemic treatments",[26],"Urothelial Neoplasm",[28],"biomarker","RECRUITING","2025-03-03",{"date":32,"type":33},"2025-03-07","ACTUAL",{"date":35,"type":33},"2023-03-01",{"date":37,"type":21},"2025-03-31",{"name":39,"class":40},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100518103","safely-reduce-cystoscopic-evaluations-for-hematuria-patients-100518103","NCT06026189","Safely Reduce Cystoscopic Evaluations for Hematuria Patients","SeARCH","Inclusion Criteria:\n\n* Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field\n* Male patients ≥40 years\n* Female patients ≥50 years\n\nExclusion Criteria:\n\n* History of urothelial bladder- or urinary tract cancer\n* Presence of macroscopic (visible) hematuria\n* Woman who is or may be pregnant",{"count":50,"type":21},1100,"INTERVENTIONAL",[53],"NA","The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.",[56,26,57,58],"Hematuria","Urothelial Carcinoma","Bladder Cancer",[60,56,57,58],"Urinary biomarker","2023-08-30",{"date":63,"type":33},"2023-09-06",{"date":65,"type":33},"2023-05-31",{"date":67,"type":21},"2027-05-31",{"name":69,"class":40},"Erasmus Medical Center",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100339378","urothelium-tissue-engineering-using-biopsies-from-transurethral-resection-of-prostate-100339378","NCT03698721","Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate","Urothelium Tissue Engineering Using Bladder Mucosa From Transurethral Resection of Prostate","IMOPU","Inclusion Criteria:\n\n* Patient needing a Transurethral Resection of Prostate (TURP)\n* Weight of prostate (evaluated by ultrasonography)greater than or equal to 30 grams\n* Affiliation to a social security system\n* Patient over the age of majority\n* Patient receiving complete information on research organization without opposition to the use of biological specimen\n\nExclusion Criteria:\n\n* Patient for whom no TURP is realized during endoscopic procedure\n* Patient for whom no resection is realized on the bladder neck\n* Patient with prostate weight estimated under 30 grams\n* Patient who opposed to the realization of the study","MALE",{"count":80,"type":21},365,"Different clinical conditions can require urinary bladder augmentation or replacement. Tissue engineered bladder has been clinically evaluated but is not recommended due to diverse side effects. Thus, there is a real interest for the development of regenerative approach with innovative scaffolds and cell transplantation.\n\nThe investigators propose the use of urothelial cells obtained by Trans-Urethral Resection of Prostate or bladder (TURP) to obtain a tissue engineered urothelium in association with different scaffolds.",[83,26,84,85,86],"Spina Bifida","Bladder, Neurogenic","Bladder Exstrophy","Hypospadias",[88,89,90,91],"Tissue engineering","Collagen scaffold","Alginate scaffold","Urothelial cells","NOT_YET_RECRUITING","2018-10-04",{"date":95,"type":33},"2018-10-09",{"date":97,"type":21},"2018-10",{"date":99,"type":21},"2026-10",{"name":101,"class":40},"Central Hospital, Nancy, France"]